Patent application number | Description | Published |
20080254473 | PREDICTING POST-TREATMENT SURVIVAL IN CANCER PATIENTS WITH MICRORNAS - This invention provides a method for predicting the post-treatment survival prospect of a cancer patient based on the expression level(s) of microRNAs hsa-miR137, hsa-miR372, hsa-miR182*, hsa-miR221, and hsa-let-7a in that cancer patient. | 10-16-2008 |
20090197798 | COMPOSITION FOR TREATING CANCER AND USE THEREOF - The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer. | 08-06-2009 |
20090220985 | RAPID EFFICACY ASSESSMENT METHOD FOR LUNG CANCER THERAPY - The present invention discloses a method for rapid assessment of lung cancer therapy efficacy in a few days instead of weeks by conventional imaging methods. This method can also be used to detect relapse of the cancer and to improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment of therapy efficacy is based on detecting circulating cancer cells in body fluid with high positive detection rate. The high positive detection rate is achieved by using qPCR amplification of multiple marker genes identified by in silico search of DNA sequence database. This invention also discloses a scoring method to calculate the cancer cell load based on qPCR results to correlate the amount of circulating cancer cells in lung cancer patients and predict the treatment outcomes. | 09-03-2009 |
20100022447 | COMPOSITION FOR TREATING CANCER AND USE THEREOF - The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer. | 01-28-2010 |
20100160414 | Treating Picornavirus Infection by Targeting MicroRNA miR-141 - Treatment of picornavirus infection by inhibiting miR-141 activity. Also disclosed herein are a method for identify miR-141 inhibitory compounds and a method for identifying a target viral infection to be treated by anti-miR-141 therapy. | 06-24-2010 |
20110224205 | USE OF CURCUMIN OR ITS ANALOGUES IN CANCER THERAPY UTILIZING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR - Provided is combined use of an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and curcumin or its analogue in cancer therapy, which reduces side effects resulting from the EGFR-TKI and reduces doses of the EGFR-TKI needed for the therapy, particular in a patient resistant to the treatment with the EGFR-TKI alone. | 09-15-2011 |
20140242580 | METHOD FOR PREDICTING RESPONSE OR PROGNOSIS OF LUNG ADENOCARCINOMA WITH EGFR-ACTIVATING MUTATIONS - The invention provides a method for predicting the response of an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a method for predicting prognosis in an EGFR-activating mutant subject suffering from a lung adenocarcinoma and receiving treatment with EGFR-TKI. In the methods of the invention, clustered genomic alterations in specific chromosomes (in particular chromosomes 5p, 7p, 8q or 14q) are determined as a tool for predicting the response or prognosis. | 08-28-2014 |
20150141485 | PROGNOSIS AND TREATMENT OF LUNG CANCER USING miRNA-135b - The present invention provides a method for the prognosis of lung cancer patient based on the expression levels of miRNA-135b, LZTS1, LATS2 and nuclear TAZ. The invention also provides a method for treatment of lung cancer. | 05-21-2015 |